The Centers for Medicare and Medicaid Services (CMS) and the Food and Drug Administration (FDA) concurrently issued decisions Aug. 11 aimed at providing access to the first noninvasive DNA screening test for colon cancer. The FDA approved Cologuard, a stool-based DNA screening test used to detect abnormalities that may indicate colon cancer. The test is…

This content is for Paid Members only.
Login Register